Mechanisms of Action of GLP-1 Agonists in T2D

April 29, 2019 12:36 pm

Expert colleagues react to the benefits demonstrated through data with the use of GLP-1 agonists for the treatment of type 2 diabetes and explore how the various options work.

Category: News
About The Author
-
Previous

GLP-1 Agonist Therapy in a Patient With T2D and CVD
Next

Type 2 Diabetes and Cardiovascular Disease: Risk Factors

Related Videos

Type-2-Diabetes-Treatments-1

A Data Integration Multi-Omics Approach to Study Calorie Restriction-Induced Changes in Insulin Sensitivity

Introduction-to-SGLT2-Inhibition

Introduction to SGLT2 Inhibition

Type-2-Diabetes-Dr-Stephen-Hull-Practical-Advice-for-People-with-T2D-and-Heart-Disease

Type 2 Diabetes: Dr Stephen Hull – Practical Advice for People with T2D and Heart Disease

Diabetologists-Perspective-of-Diabetes-and-Cardiovascular-Risk-Management-in-Post-ACS-T2D-patients

Diabetologist’s Perspective of Diabetes and Cardiovascular Risk Management in Post-ACS T2D patients

Preview-A-low-carb-diet-for-T2D-reversal-Dr.-Sarah-Hallberg

[Preview] A low-carb diet for T2D reversal – Dr. Sarah Hallberg

Sodium-Glucose-Transporter-2-Inhibition-An-Important-Advancement-for-Patients-with-T2D-and-CKD

Sodium-Glucose Transporter-2 Inhibition: An Important Advancement for Patients with T2D and CKD